chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Approximately 7 days after got vaccine arm became itchy, hot, red and swollen w/pain - Treated w/Zyrtec, Benadryl, and clindamycin - symptoms improved over 4 days
Moderna COVID-19 Vaccine EUA  Rash: red, mostly round, sometimes raised, sometimes with blisters. Have continued to appear on legs, arms, torso over last week. Very, very itchy.  Not at all responsive to cortisone cream. Benadryl topical helps a little.
swollen optic nerve and lost 50% vision in one eye; swollen optic nerve and lost 50% vision in one eye; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A male patient received BNT162b2 (BNT162B2), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete but unknown manufacturer), for COVID-19 immunization. The following information was reported: BLINDNESS (medically significant), PAPILLOEDEMA (medically significant), outcome "unknown" and all described as "swollen optic nerve and lost 50% vision in one eye".  Clinical information: Caller stated, after receiving Pfizer Covid vaccine booster, he experienced swollen optic nerve and lost 50% vision in one eye. Caller was seeking information on any other cases.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
History of having stopped breathing on 7-27-10 (A.M.). Turned blue - patted on back; blowing into mouth via GM. Lethargic about 5 mins. Transported to ER.
I have a 6 inch rash on my upper left arm at the site of injection.  It is 3 inches wide and covers most of my upper arm.   It is beginning to be sore like it was the first 2 days after injection.  I totally forgot that 10 years ago I had a bad itching reaction to every deodorant I tried.  I decided it was the aluminum.  I have been using deodorant with no aluminum and have had no reaction for the last 10 years.  It never occurred to me to note it on the paper work  I  filled out.    Also when the nurse asked me if I had allergies I said no.
Evening of 8/26 I started to have flu like symptoms along with muscle. The flu like symptoms worsened on 8/27. I was nausea, dizzy and feverish. I slept all day. The muscle pain worsened on 8/27 & 8/28. I had limited range of motion for 2 day. The flu like symptoms went away on 8/28. As the week, progressed, muscle pain improved. As of today 9/2, I still have muscle pain and having difficulty dressing using my left arm. I'm not totally recovered. I expected some muscle pain but is a week since the shot.
Presented with aphasia, left sided weakness and facial droop, diagnosed with multiple cerebral aneurysms and likely TIA. No interventions were done at the time as she was outside of window for tPA and NIH was 2. Atrial fibirllation managed with rate control medications. Patient reported similar symptoms happened a year prior and lasted about 3 days, then resolved. She did not seek medical treatment/evaluation at that time.
Pt recvd 3 Hep B vax on 26JUL89, 6SEP89, & 25JAN90 & on 8MAR90 titer=159; 7MAR91 titer=8; given 4th vax dose on 11APR91 following this titer=186;
tching in her arm; d spot 6 inches and long 4 inches wide at the injection site; large spot 6 inches and long 4 inches wide at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (tching in her arm), VACCINATION SITE ERYTHEMA (d spot 6 inches and long 4 inches wide at the injection site) and ERYTHEMA (large spot 6 inches and long 4 inches wide at the injection site) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID), METOPROLOL, HYDROCHLOROTHIAZIDE and statin for an unknown indication.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, the patient experienced PRURITUS (tching in her arm), VACCINATION SITE ERYTHEMA (d spot 6 inches and long 4 inches wide at the injection site) and ERYTHEMA (large spot 6 inches and long 4 inches wide at the injection site). At the time of the report, PRURITUS (tching in her arm), VACCINATION SITE ERYTHEMA (d spot 6 inches and long 4 inches wide at the injection site) and ERYTHEMA (large spot 6 inches and long 4 inches wide at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included 1 2 Benadryl. Cortisone cream.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This is a spontaneous report from a contactable nurse via a Pfizer-sales representative. A patient of unspecified age and gender received TRUMENBA, via an unspecified route of administration on an unspecified date at a single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient experienced numbness, dizziness, and tingling on an unspecified date. The outcome of all events was unknown. Information on batch number has been requested.
This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered 4 doses of the bivalent vaccine which was beyond the 30 day BUD), PRODUCT STORAGE ERROR (vials were initially stored in the refrigerator on 21-Jan-2023 and administered on 26-Feb-2023) and NO ADVERSE EVENT (No adverse event) in a 6-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 059F22A) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (Dose 1) on 16-Nov-2021, PFIZER BIONTECH COVID-19 VACCINE (Dose 2) on 10-Dec-2021 and PFIZER BIONTECH COVID-19 VACCINE (Dose 3) on 26-May-2022. Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE, PFIZER BIONTECH COVID-19 VACCINE and PFIZER BIONTECH COVID-19 VACCINE.
Mild left salivary gland inflammation and parotitis.  Treatment - alternate ibuprofen and Tylenol; cool compress as tolerated.
THURSDAY STARTED WITH CHILLS AND SEVERE BACK PAIN ALONG THE BELT LINE.  HE CALLED (PCP).  COMPLAINED OF SOB (SHORTNESS OF BREATH).  NO FEVER.  AUDIBLE SOB SO HEALTHCARE PROVIDER INSTRUCTED THE PATIENT TO GO TO THE URGENT CARE OR CALL DR. ASAP.
This case was reported by a healthcare professional and described the occurrence of swelling of face in a female subject aged between 20 and 29 years old who was vaccinated with FLULAVAL (GlaxoSmithKline). On 19 September 2012 at 08:00 the subject received unspecified dose of FLULAVAL (unknown). On 19 September 2012, within hours of vaccination with FLULAVAL, the subject experienced swelling of face. The healthcare professional indicated that the vaccine was administered to the subject in the 08:00 time frame and the face swelled up was reported after "they" had left the site at about 10-10:30. At the time of reporting the outcome of the facial swelling was unspecified.
Discharge Provider:  Primary Care Provider: MD Admission Date: 5/29/2022 Discharge Date: 6/3/22  PRESENTING PROBLEM: Cough Acute respiratory failure with hypoxia COVID-19   Brief history and medical decision making: s/p lung tranpslant, covid-19 pneumonia, admitted with hypoxemic respiratory failure with bilateral lung infiltrates possibly due to aspiration pneumonia vs. Post covid inflammatory pneumonia. Improving with steroids and antibiotics. Complete course as described below. Will have a telemedicine review to ensure symptoms are improving next week. Follow up in clinic in 2-3 weeks with CXR, PFT, oxygen titration study. Can likely increase MMF to previous goal dose next week if clinically stable and steroids are back to baseline. Needs work up pancreatic lesion and aspiration concerns.
LOC with cardiac arrest within 15 minutes of injection. CPR started and patient did recover on his own. EMS transported to ED.
Headache, fever, shaking, nausea, diahhrea, body aches, dizziness, cough and heart racing.  This last for about 48 hours.  This is day7 and I still nausea and no energy.
low grade fever (99°F); muscle pain on her arm/pain on her arm; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (low grade fever (99°F)) and INJECTION SITE PAIN (muscle pain on her arm/pain on her arm) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID) and ATORVASTATIN for an unknown indication, LOSARTAN.   On 08-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 2 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 11-Jan-2021, the patient experienced INJECTION SITE PAIN (muscle pain on her arm/pain on her arm). On 08-Feb-2021, the patient experienced PYREXIA (low grade fever (99°F)). On 09-Feb-2021, PYREXIA (low grade fever (99°F)) had resolved. At the time of the report, INJECTION SITE PAIN (muscle pain on her arm/pain on her arm) outcome was unknown.            No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not applicable .
vomiting; diarrhea/Lingering diarrhea into second day; ringing in my left ear. LOUD!; excessive urination; eyes feeling like they were popping out; tunnel vision; 104 fever; severe chills and quaking; severe chills and quaking; the worst headache in my life/slight headache on the back of my head, and continued into today; felt like broken shins; hip joints on fire; This is a spontaneous report from a contactable consumer herself (patient). A 60-years-old female patient received second dose bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Solution for injection), via an unspecified route of administration, administered in Arm Left on 22Mar2021 (Batch/Lot Number: EN6204) Solution for injection as Single Dose for covid-19 immunisation. Medical history included asthma, mild HP (Hypersensitivity pneumonitis) and I am fat. Concomitant medications included lovastatin, eszopiclone (LUNESTA), lisinopril and gabapentin. The patient previously took first dose of BNT162B2 (EN6198), on Left arm on 27Feb2021 for Covid-19 immunization. On 23Mar2021 02:00 patient experienced 104 fever, severe chills and quaking, the worst headache in my life, what felt like broken shins another friend said she had this as well, hip joints on fire, eyes feeling like they were popping out, vomiting after hours 26, tunnel vision, excessive urination, diarrhea started at hour 28. Lingering diarrhea into second day, slight headache on the back of her head, and continued into today, ringing in her left ear. The patient underwent lab tests and procedures which included body temperature: 104 on 23Mar2021. Patient did not test covid post vaccination. Patient did not have covid prior vaccination. The outcome of all events was recovered with sequelae.
No other adverse events reported; Improperly stored vaccine was administered yesterday; This spontaneous report was received from a licensed practical nurse concerning a patient of unknown age and gender. The patient's concurrent conditions, concomitant medications, historical conditions and drug allergies or reactions were not reported.   On 18-MAR-2021 (also reported as "yesterday"), the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), prefilled syringe,  lot # 1687292 with an expiration date reported and validated as 25-AUG-2022 , at the dose of 0.5 milliliter intramuscular for prophylaxis (strength, anatomical location, dose number were not reported) that was improperly stored (product storage error). No other adverse events/effects reported. No product quality complaint.  The administered vaccine experienced a temperature of 47.1 Fahrenheit for a time frame of 10 minutes. It was stated that no previous temperature excursion and a data logger was involved.  This is one of the several reports received from the same reporter. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: 1687292; expirationdate: 25-AUG-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2103USA006091: US-009507513-2103USA006100: US-009507513-2103USA006101:
Patient received DTAP & VZV on right arm, following morning right arm swollen & red & painful about 2 1/2 in X 4 in area.
Information has been received from a physician concerning a female pt with a medical history of a previous meningioma that had been removed and a seizure problem following the craniotomy. It was reported that the pt had been doing fine and was off all of her anticonvulsant medications for one year. The pt became pregnant and had an uncomplicated course of pregnancy. She was hospitalized and was delivered by caesarean section for past history reasons. It was noted that the pt had not had a seizure during the entire pregnancy. Laboratory evaluation revealed that the pt was rubella non-immune and while she was hospitalized for the caesarean section she was vaccinated postpartum on an unspecified date with a dose of rubella virus vaccine live II (lot not reported).  The pt experienced a seizure three hours after receiving the vaccine and then experienced several more seizures. The treatment for the seizures was Depakote IV. On 3/11/03, the physician reported that the pt had been discharged from the hospital and had recovered. The physician reported that the pt was not breastfeeding. The physician reported that he did not think there was any relationship between the vaccine and the seizure and that he doubted a connection. Upon internal review, seizures was considered to be an other important medical event (OMIC). Additional info has been requested.
This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION COMPLICATION (Had a bad reaction to the booster, given three days ago.  Still having side effects.) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Had a bad reaction to the booster, given three days ago.  Still having side effects.). At the time of the report, VACCINATION COMPLICATION (Had a bad reaction to the booster, given three days ago.  Still having side effects.) had not resolved. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. Concomitant product use was not provided by the reporter.  No treatment information provided.
patient's spleen enlarged 6 times the normal size; has had itching from head to toe; left arm pit is also swollen.; had fever,; arm of the injection has been red from her shoulder to her elbow; arm of the injection has been swollen from her shoulder to her elbow.; aches; joint pain; This spontaneous case was reported by a pharmacist and describes the occurrence of SPLENOMEGALY (patient's spleen enlarged 6 times the normal size), PRURITUS (has had itching from head to toe), LYMPHADENOPATHY (left arm pit is also swollen.), PYREXIA (had fever,) and VACCINATION SITE ERYTHEMA (arm of the injection has been red from her shoulder to her elbow) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 23-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2021, the patient experienced SPLENOMEGALY (patient's spleen enlarged 6 times the normal size), PRURITUS (has had itching from head to toe), LYMPHADENOPATHY (left arm pit is also swollen.), PYREXIA (had fever,), VACCINATION SITE ERYTHEMA (arm of the injection has been red from her shoulder to her elbow), VACCINATION SITE SWELLING (arm of the injection has been swollen from her shoulder to her elbow.), MYALGIA (aches) and ARTHRALGIA (joint pain). At the time of the report, SPLENOMEGALY (patient's spleen enlarged 6 times the normal size), LYMPHADENOPATHY (left arm pit is also swollen.), PYREXIA (had fever,), VACCINATION SITE ERYTHEMA (arm of the injection has been red from her shoulder to her elbow), VACCINATION SITE SWELLING (arm of the injection has been swollen from her shoulder to her elbow.), MYALGIA (aches) and ARTHRALGIA (joint pain) outcome was unknown and PRURITUS (has had itching from head to toe) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.
Patient tested positive for COVID-19 on 8/9/2021 - admitted to hospital with Fever, chills, body aches, fatigue, nausea, vomiting, diarrhea, cough. Patient described issue with immunosuppressive medication since 7/29 due to problem with auto-refill, picked up refills late on 8/4 and has been only intermittently compliant due to nausea. On 8/5, she developed fever to 101.5 F, chills, body aches, fatigue, non-bilious non-bloody vomiting, watery-brown diarrhea, and mild cough productive of clear sputum for which she sought further evaluation here 8/9. No chest pain or dyspnea. No abdominal pain or flank pain. In the ED, vitals WNL. Labs notable for AKI to 2.02 (baseline Cr 1.29). CXR with possible R lower lung field atypical pneumonia. COVID PCR positive. Procal 4.05. Lactate WNL. Admitted to Medicine, placed on Decadron and given IV fluids.
sore arm; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (sore arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYALGIA (sore arm). At the time of the report, MYALGIA (sore arm) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       No concomitant medications were reported.  No corrective treatment was provided.
Narrative:  Patient reports that since his 2nd vaccine he has had intermittent L shoulder pain that feels similar to the injection pain he felt on the day of the vaccine.
Information, originating from a physician, has been received concerning 4 pts who were vaccinated with a dose of pneumococcal vaccine 23 polyvalent (lot 640744/0994L) (WAES0201USA03353). The physician stated he vaccinated 6 pts and within 24 hours, post vax, 4 of the pts developed "red, swollen arm, local site reaction and nausea". The reporter was told by a physician that "he heard of the same kind of reaction at a local hospital and another doctor office with the same lot number". It was reported that the physician would like the lot to be checked. The reporter stated that after the pts were vaccinated, "the left over vaccine was left at room temperature". It was reported to be unknown if the pts sought medical attention. Follow up information has been received from a physician concerning 1 of the pts. It was reported that a 94 year old white female pt, on 11/7/01, at 11:00, was vaccinated with a 1st dose of pneumococcal vaccine 23 polyvalent (lot 640744/0994L). The physician reported that the pt had swelling, redness, fever and infection starting on 11/7/01. She was placed on antibiotics and the recovery status was reported as unknown. The records of testing prior to release of this lot have been checked by compliance and found to be satisfactory. The lot complies with the standards and released. Upon internal review, the swelling, redness, fever and infection were considered to be "Other Important Medical Events". Follow up info indicated that the pt recovered from the events.
This case was reported by a healthcare professional and described the occurrence of not responding to therapy in an adult subject of unspecified gender who was vaccinated with Engerix-B (GlaxoSmithKline). The healthcare professional reported that more than one subject did not respond to immunization to Engerix-B, however a specific number of subjects was not reported. On an unspecified date on or before 11 December 2006, the subject received unspecified dose of Engerix-B. At an unspecified time after vaccination with Engerix-B, on an unspecified date on or before 11 December 2006, a hepatitis B surface antibody titer indicated that the subject "did not respond to Engerix-B." The subject was seen by a physician.
Client received Pfizer as first dose and Moderna as second dose in primary series. Pt was monitored post vaccination for 15 minutes, no adverse events noted.
This case was reported by a physician via sales rep and described the occurrence of vaccination failure in a adult patient who received SHINGRIX. On an unknown date, the patient received SHINGRIX. On an unknown date, 61 days after receiving SHINGRIX, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and rash. On an unknown date, the outcome of the vaccination failure, shingles and rash were unknown. It was unknown if the reporter considered the vaccination failure, shingles and rash to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported, however it could be 50 and above. The patient developed shingles approximately 2 months later and the patient experienced visible rash and no pain was associated with it. The reporter was not sure of correlation with vaccine. The reporter did not provide the details and information on completion of dosing regiment, specifically whether the patient received the 2nd dose. The reported agreed to be followed up. This case was considered as suspected vaccination failure as primary vaccination schedule completion and confirmation of lab test details were unknown.
6 hours after the injection the following side effects started: 1) headache 2) severe muscle aches 3) nausea 4) fever throughout the night spiking at 103.4  The following day Headache, muscle aches and fever continued.
On first day I had stuffy nose and headache. I tested because I had just gotten back from a funeral. Next day I was stuffy, congested, and slight fever. After PAXLOVID, symptoms went away after about the 4th day. Last Friday I started having symptoms again due to rebound.
All lymph nodes hurt in upper body. Mostly neck. Feels like pins and needles. Sometime starts in stomac and radiates into arms back into neck then sensation stops once it reaches head.